# Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors

> **NCT04890093** · PHASE1,PHASE2 · SUSPENDED · sponsor: **National Cancer Institute (NCI)** · enrollment: 64 (estimated)

## Conditions studied

- Sarcoma, Ewing
- Rhabdomyosarcoma

## Interventions

- **DRUG:** PEN-866
- **DRUG:** Vincristine
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04890093
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2024-10-31
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Why stopped:** Pending updated agreements in order to enroll additional participants.
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04890093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04890093, "Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04890093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*